Tangui Maurice

Montpellier, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Sigma 1 receptor agonists: the new trend or an emerging therapeutic option?

Sigma 1 receptor agonists: the new trend or an emerging therapeutic option?

Journal: Expert opinion on emerging drugs

Published: June 29, 2026

Enhanced cognitive protection through the combination of Amylovis-201, an anti-amyloidogenic agent with sigma-1 receptor agonist activity, and environmental enrichment in mice.

Enhanced cognitive protection through the combination of Amylovis-201, an anti-amyloidogenic agent with sigma-1 receptor agonist activity, and environmental enrichment in mice.

Journal: Journal of psychopharmacology (Oxford, England)

Published: June 24, 2026

Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer's Disease.

Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer's Disease.

Journal: ACS chemical neuroscience

Published: April 13, 2026

Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer's Disease.

Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer's Disease.

Journal: ACS chemical neuroscience

Published: April 13, 2026

Development of Second-Generation Phenoxyethylpiperidines as Potent Sigma-1 Receptor Agonists with Neuroprotective Potential for Alzheimer's Disease.

Development of Second-Generation Phenoxyethylpiperidines as Potent Sigma-1 Receptor Agonists with Neuroprotective Potential for Alzheimer's Disease.

Journal: Journal of medicinal chemistry

Published: February 05, 2026

A Dual Approach To Combat Alzheimer's Disease through Concomitant hBChE Inhibition and S1R Activation.

A Dual Approach To Combat Alzheimer's Disease through Concomitant hBChE Inhibition and S1R Activation.

Journal: ACS chemical neuroscience

Published: January 27, 2026

Access to novel potent pleiotropic prodrugs, targeting both butyrylcholinesterase and serotonin reuptake, with anti-amnesic activities in Alzheimer's disease model.

Access to novel potent pleiotropic prodrugs, targeting both butyrylcholinesterase and serotonin reuptake, with anti-amnesic activities in Alzheimer's disease model.

Journal: European journal of medicinal chemistry

Published: January 15, 2026

Xanthatin-13-(Pyrrolidine-2-Carboxylic Acid), a Sesquiterpene Lactone Isolated From Burdock Leaf, Attenuated Aβ25-35 Toxicity and Memory Deficits in a Pharmacological Mouse Model of Alzheimer's Disease.

Xanthatin-13-(Pyrrolidine-2-Carboxylic Acid), a Sesquiterpene Lactone Isolated From Burdock Leaf, Attenuated Aβ25-35 Toxicity and Memory Deficits in a Pharmacological Mouse Model of Alzheimer's Disease.

Journal: Phytotherapy research : PTR

Published: December 30, 2025

Targeting neuroinflammation by activation of the sigma-1 receptor (S1R) and inhibition of butyrylcholinesterase (hBChE) leads to highly potent anti-amnesic compounds in an Alzheimer's disease mouse model.

Targeting neuroinflammation by activation of the sigma-1 receptor (S1R) and inhibition of butyrylcholinesterase (hBChE) leads to highly potent anti-amnesic compounds in an Alzheimer's disease mouse model.

Journal: European journal of medicinal chemistry

Published: October 21, 2025

Sigma-1-targeting multimodal compound HBK-15 reverses memory deficits and restores hippocampal plasticity under NMDA hypofunction.

Sigma-1-targeting multimodal compound HBK-15 reverses memory deficits and restores hippocampal plasticity under NMDA hypofunction.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: September 08, 2025

Vitamin K-Trolox synergism realized in hybrid neuroprotectant with potent anti-ferroptosi/oxytosis activity, reduced toxicity, and in vivo efficacy in Alzheimer's disease mouse model.

Vitamin K-Trolox synergism realized in hybrid neuroprotectant with potent anti-ferroptosi/oxytosis activity, reduced toxicity, and in vivo efficacy in Alzheimer's disease mouse model.

Journal: European journal of medicinal chemistry

Published: June 30, 2025

Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer's disease model.

Prevention of memory impairment and hippocampal injury with blarcamesine in an Alzheimer's disease model.

Journal: Neuroscience letters

Published: June 19, 2025

Showing 1-12 of 111

Last Updated: 09/26/2026